Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma.

J Immunother Cancer 2015 21;3:11. Epub 2015 Apr 21.

Division of Medical Oncology, University Hospital Basel, Basel, Switzerland.

Antibodies that stimulate the immune system by targeting inhibitory T cell receptors were successfully introduced into oncological practice and are capable to overcome tumor-induced immune evasion. In particular, targeting of the inhibitory receptors CTLA-4 and PD-1 or its ligand PD-L1 have been shown to be beneficial for patients with melanoma, renal cell cancer, non-small cell lung cancer and a growing list of other cancers with impressive response rates. Here, we report a severe, potentially life-threatening side effect of anti-PD-1 immunotherapy with pembrolizumab, which has not been previously described in the literature. A 73-year-old woman with metastatic uveal melanoma treated with pembrolizumab in third line developed severe heart failure due to pembrolizumab-mediated autoimmune myocarditis. Echocardiographic studies revealed a severely impaired left ventricular function with dyssynchrony. All tests for cardiotropic viruses were negative and histological analysis of a myocardial biopsy showed lymphocytic infiltration with a predominance of CD8 positive cells and a reduction of FOXP3 positive regulatory T cells. After initiation of corticosteroids and guideline-conform heart failure therapy, the symptoms rapidly improved and the left ventricular function recovered. While autoimmune myocarditis is a documented side effect of other checkpoint inhibitors, as for example ipilimumab and in one case with anti-PD-L1 antibody, it is not described for anti-PD-1-antibodies like pembrolizumab or nivolumab. As the FDA recently approved both pembrolizumab and nivolumab for melanoma progressing after anti-CTLA-4 treatment with ipilimumab, more patients will soon receive anti-PD-1 therapy. Thus, it is important to be aware of such rare, but severe immune-related adverse events.

Download full-text PDF

Source
http://jitc.biomedcentral.com/articles/10.1186/s40425-015-00
Publisher Site
http://dx.doi.org/10.1186/s40425-015-0057-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404586PMC
April 2015
24 Reads

Publication Analysis

Top Keywords

heart failure
12
autoimmune myocarditis
12
targeting inhibitory
8
left ventricular
8
ventricular function
8
pembrolizumab nivolumab
8
pembrolizumab
5
viruses negative
4
negative histological
4
histological analysis
4
cardiotropic viruses
4
analysis myocardial
4
tests cardiotropic
4
anti-pd-1 immunotherapy
4
function dyssynchrony
4
dyssynchrony tests
4
myocardial biopsy
4
biopsy lymphocytic
4
cells reduction
4
reduction foxp3
4

References

(Supplied by CrossRef)

SA Rosenberg et al.
Nature 2001

DB Page et al.
Annu Rev Med 2014

FS Hodi et al.
N Engl J Med 2010

C Robert et al.
N Engl J Med 2011

SM Ansell et al.
N Engl J Med 2015

C Robert et al.
Lancet 2014

O Hamid et al.
N Engl J Med 2013

JR Brahmer et al.
N Engl J Med 2012

SL Topalian et al.
N Engl J Med 2012

JD Wolchok et al.
N Engl J Med 2013

Similar Publications